941 related articles for article (PubMed ID: 17499406)
1. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
[TBL] [Abstract][Full Text] [Related]
2. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.
Joura EA; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch X; Dillner J; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Lu S; Vuocolo S; Hesley TM; Haupt RM; Barr E
Vaccine; 2008 Dec; 26(52):6844-51. PubMed ID: 18930097
[TBL] [Abstract][Full Text] [Related]
3. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.
Villa LL; Ault KA; Giuliano AR; Costa RL; Petta CA; Andrade RP; Brown DR; Ferenczy A; Harper DM; Koutsky LA; Kurman RJ; Lehtinen M; Malm C; Olsson SE; Ronnett BM; Skjeldestad FE; Steinwall M; Stoler MH; Wheeler CM; Taddeo FJ; Yu J; Lupinacci L; Railkar R; Marchese R; Esser MT; Bryan J; Jansen KU; Sings HL; Tamms GM; Saah AJ; Barr E
Vaccine; 2006 Jul; 24(27-28):5571-83. PubMed ID: 16753240
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy of human papillomavirus vaccination.
Ault KA
Gynecol Oncol; 2007 Nov; 107(2 Suppl 1):S27-30. PubMed ID: 17938016
[TBL] [Abstract][Full Text] [Related]
5. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
[TBL] [Abstract][Full Text] [Related]
6. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine.
Giuliano AR; Lazcano-Ponce E; Villa L; Nolan T; Marchant C; Radley D; Golm G; McCarroll K; Yu J; Esser MT; Vuocolo SC; Barr E
J Infect Dis; 2007 Oct; 196(8):1153-62. PubMed ID: 17955433
[TBL] [Abstract][Full Text] [Related]
7. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine.
Fraser C; Tomassini JE; Xi L; Golm G; Watson M; Giuliano AR; Barr E; Ault KA
Vaccine; 2007 May; 25(21):4324-33. PubMed ID: 17445955
[TBL] [Abstract][Full Text] [Related]
8. Measuring serum antibody to human papillomavirus following infection or vaccination.
Frazer IH
Gynecol Oncol; 2010 Jun; 118(1 Suppl):S8-11. PubMed ID: 20494221
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence.
Bonanni P; Boccalini S; Bechini A
Vaccine; 2009 May; 27 Suppl 1():A46-53. PubMed ID: 19480962
[TBL] [Abstract][Full Text] [Related]
10. Correlating immunity with protection for HPV infection.
Frazer I
Int J Infect Dis; 2007 Nov; 11 Suppl 2():S10-6. PubMed ID: 18162240
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes...
Prescrire Int; 2007 Jun; 16(89):91-4. PubMed ID: 17582921
[TBL] [Abstract][Full Text] [Related]
12. The prophylactic role for the human papillomavirus quadrivalent vaccine in males.
Yancey AM; Pitlick JM; Forinash AB
Ann Pharmacother; 2010; 44(7-8):1314-8. PubMed ID: 20501891
[TBL] [Abstract][Full Text] [Related]
13. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials.
Paavonen J;
Curr Med Res Opin; 2008 Jun; 24(6):1623-34. PubMed ID: 18435868
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial.
Poland GA; Jacobson RM; Koutsky LA; Tamms GM; Railkar R; Smith JF; Bryan JT; Cavanaugh PF; Jansen KU; Barr E
Mayo Clin Proc; 2005 May; 80(5):601-10. PubMed ID: 15887427
[TBL] [Abstract][Full Text] [Related]
16. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
Hantz S; Alain S; Denis F
Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
[TBL] [Abstract][Full Text] [Related]
17. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.
Garland SM; Steben M; Sings HL; James M; Lu S; Railkar R; Barr E; Haupt RM; Joura EA
J Infect Dis; 2009 Mar; 199(6):805-14. PubMed ID: 19199546
[TBL] [Abstract][Full Text] [Related]
18. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine.
Ault KA; Giuliano AR; Edwards RP; Tamms G; Kim LL; Smith JF; Jansen KU; Allende M; Taddeo FJ; Skulsky D; Barr E
Vaccine; 2004 Aug; 22(23-24):3004-7. PubMed ID: 15297048
[TBL] [Abstract][Full Text] [Related]
19. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
[TBL] [Abstract][Full Text] [Related]
20. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy.
Lehtinen M; Idänpään-Heikkilä I; Lunnas T; Palmroth J; Barr E; Cacciatore R; Isaksson R; Kekki M; Koskela P; Kosunen E; Kuortti M; Lahti L; Liljamo T; Luostarinen T; Apter D; Pukkala E; Paavonen J
Int J STD AIDS; 2006 Apr; 17(4):237-46. PubMed ID: 16595046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]